Sp381
ANTI-INTEGRIN AND ANTI-IL-23 THERAPIES — THE NEXT BEST THING?
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring. This session will review the role of historic and emerging biologics for management of CD and UC, examine comparative efficacy and safety and define the concepts of therapeutic drug monitoring, combinational biologic therapy, and rational de-escalation.
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring. This session will review the role of historic and emerging biologics for management of CD and UC, examine comparative efficacy and safety and define the concepts of therapeutic drug monitoring, combinational biologic therapy, and rational de-escalation.
Presenter
Tracks
Related Products
PANEL DISCUSSION
There are multiple new biologic agents that have been approved for the management of IBD over the past few years. In addition, high quality randomized controlled trials have examined optimization of these treatments through therapeutic drug monitoring…
ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
ANTI-INTEGRIN αVβ6 AUTOANTIBODIES ARE A NOVEL PREDICTIVE BIOMARKER IN ULCERATIVE COLITIS
Aconitate decarboxylase 1 (ACOD1; also known as IRG-1) is the ubiquitous source of the metabolite itaconate, which dampens inflammasome activation by preventing HIF1α production of IL-1β and prevents TNF production through NRF2 activation…
ANTI-GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR AUTOANTIBODIES ARE ASSOCIATED WITH DEVELOPMENT OF COMPLICATIONS IN RECENTLY DIAGNOSED CROHN’S DISEASE PATIENTS
BACKGROUND: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (anti-GM-CSF) have been associated with development of Crohn’s disease (CD) and complications at time of diagnosis. There are limited data on anti-GM-CSF as a prognostic biomarker in CD…